Trade Novartis - CHF - NOVN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.35 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.015687% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.006535% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | CHF | ||||||||
Margin | 5% | ||||||||
Stock exchange | Switzerland | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Novartis AG ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 84.6 |
Open* | 84.55 |
1-Year Change* | 1.81% |
Day's Range* | 84.35 - 84.75 |
52 wk Range | 69.89-90.16 |
Average Volume (10 days) | 2.80M |
Average Volume (3 months) | 64.62M |
Market Cap | 195.93B |
P/E Ratio | 27.61 |
Shares Outstanding | 2.06B |
Revenue | 42.32B |
EPS | 3.12 |
Dividend (Yield %) | 3.72093 |
Beta | 0.95 |
Next Earnings Date | Jan 31, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 29, 2023 | 84.60 | -0.55 | -0.65% | 85.15 | 85.70 | 84.20 |
Nov 28, 2023 | 85.15 | -0.75 | -0.87% | 85.90 | 86.20 | 84.80 |
Nov 27, 2023 | 85.85 | -0.50 | -0.58% | 86.35 | 86.50 | 85.75 |
Nov 24, 2023 | 86.45 | 0.35 | 0.41% | 86.10 | 86.55 | 85.90 |
Nov 23, 2023 | 85.95 | 0.35 | 0.41% | 85.60 | 86.00 | 85.35 |
Nov 22, 2023 | 85.80 | 1.05 | 1.24% | 84.75 | 86.35 | 84.75 |
Nov 21, 2023 | 84.95 | 0.80 | 0.95% | 84.15 | 85.10 | 83.95 |
Nov 20, 2023 | 84.20 | 0.80 | 0.96% | 83.40 | 84.30 | 83.40 |
Nov 17, 2023 | 83.95 | 0.55 | 0.66% | 83.40 | 84.25 | 83.05 |
Nov 16, 2023 | 82.85 | -0.65 | -0.78% | 83.50 | 83.90 | 82.85 |
Nov 15, 2023 | 83.40 | -0.85 | -1.01% | 84.25 | 84.35 | 82.85 |
Nov 14, 2023 | 84.00 | -0.80 | -0.94% | 84.80 | 85.05 | 84.00 |
Nov 13, 2023 | 84.30 | 0.35 | 0.42% | 83.95 | 84.40 | 83.70 |
Nov 10, 2023 | 83.65 | -0.80 | -0.95% | 84.45 | 84.85 | 83.25 |
Nov 9, 2023 | 84.15 | -0.85 | -1.00% | 85.00 | 85.00 | 83.90 |
Nov 8, 2023 | 84.65 | 0.65 | 0.77% | 84.00 | 85.20 | 83.65 |
Nov 7, 2023 | 83.95 | 0.05 | 0.06% | 83.90 | 84.35 | 83.45 |
Nov 6, 2023 | 83.95 | 0.70 | 0.84% | 83.25 | 84.05 | 82.95 |
Nov 3, 2023 | 83.15 | -1.35 | -1.60% | 84.50 | 84.65 | 82.80 |
Nov 2, 2023 | 84.35 | -0.50 | -0.59% | 84.85 | 85.05 | 83.55 |
Novartis - CHF Events
Time (UTC) | Country | Event |
---|---|---|
Monday, January 8, 2024 | ||
Time (UTC) 10:59 | Country CH
| Event Novartis AG at JPMorgan Healthcare Conference Novartis AG at JPMorgan Healthcare ConferenceForecast -Previous - |
Monday, January 29, 2024 | ||
Time (UTC) 07:30 | Country CH
| Event Q4 2023 Novartis AG Earnings Release Q4 2023 Novartis AG Earnings ReleaseForecast -Previous - |
Wednesday, March 6, 2024 | ||
Time (UTC) 09:00 | Country CH
| Event Novartis AG Annual Shareholders Meeting Novartis AG Annual Shareholders MeetingForecast -Previous - |
Monday, April 22, 2024 | ||
Time (UTC) 06:30 | Country CH
| Event Q1 2024 Novartis AG Earnings Release Q1 2024 Novartis AG Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 51742 | 52877 | 49898 | 48624 | 46017 |
Revenue | 51742 | 52877 | 49898 | 48624 | 46017 |
Cost of Revenue, Total | 14998 | 15435 | 14400 | 13930 | 13555 |
Gross Profit | 36744 | 37442 | 35498 | 34694 | 32462 |
Total Operating Expense | 42545 | 41188 | 39746 | 39538 | 31824 |
Selling/General/Admin. Expenses, Total | 14190 | 14815 | 14093 | 14319 | 13690 |
Research & Development | 9088 | 9041 | 8484 | 8386 | 8154 |
Depreciation / Amortization | 158 | 109 | 64 | 50 | 179 |
Unusual Expense (Income) | 3402 | 1173 | 2503 | 2284 | -4309 |
Other Operating Expenses, Total | 449 | 653 | 538 | 607 | 549 |
Operating Income | 9197 | 11689 | 10152 | 9086 | 14193 |
Interest Income (Expense), Net Non-Operating | -543 | 14628 | -146 | -36 | -5 |
Other, Net | -283 | -180 | -128 | -110 | -93 |
Net Income Before Taxes | 8371 | 26137 | 9878 | 8940 | 14095 |
Net Income After Taxes | 6955 | 24018 | 8071 | 7147 | 12800 |
Minority Interest | 0 | 3 | 1 | -5 | -3 |
Net Income Before Extra. Items | 6955 | 24021 | 8072 | 7142 | 12797 |
Net Income | 6955 | 24021 | 8072 | 11732 | 12611 |
Income Available to Common Excl. Extra. Items | 6955 | 24021 | 8072 | 7142 | 12797 |
Income Available to Common Incl. Extra. Items | 6955 | 24021 | 8072 | 11732 | 12611 |
Dilution Adjustment | |||||
Diluted Net Income | 6955 | 24021 | 8072 | 11732 | 12611 |
Diluted Weighted Average Shares | 2197 | 2260 | 2296 | 2319 | 2344 |
Diluted EPS Excluding Extraordinary Items | 3.16568 | 10.6288 | 3.51568 | 3.07978 | 5.45947 |
Dividends per Share - Common Stock Primary Issue | 3.46171 | 3.19907 | 3.38945 | 3.04815 | 2.90402 |
Diluted Normalized EPS | 4.47075 | 11.1183 | 4.40641 | 3.86715 | 3.79006 |
Total Extraordinary Items | 4590 | -186 | |||
Interest Expense (Income) - Net Operating | 260 | -38 | -336 | -38 | 6 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total revenue | 12092 | 22792 | 13208 | 13001 | 10783 |
Revenue | 12092 | 22792 | 13208 | 13001 | 10783 |
Cost of Revenue, Total | 3089 | 5944 | 3829 | 3837 | 2874 |
Gross Profit | 9003 | 16848 | 9379 | 9164 | 7909 |
Total Operating Expense | 10330 | 17367 | 10352 | 11052 | 8957 |
Selling/General/Admin. Expenses, Total | 3093 | 5952 | 3401 | 3699 | 2936 |
Research & Development | 2187 | 4182 | 2272 | 2318 | 2542 |
Depreciation / Amortization | 169 | 198 | 153 | 42 | |
Interest Expense (Income) - Net Operating | -6 | 69 | 46 | -28 | 90 |
Unusual Expense (Income) | 1751 | 648 | 298 | 1145 | 302 |
Other Operating Expenses, Total | 47 | 374 | 353 | 39 | 213 |
Operating Income | 1762 | 5425 | 2856 | 1949 | 1826 |
Interest Income (Expense), Net Non-Operating | -225 | -420 | -212 | -222 | -211 |
Other, Net | 15 | 189 | 96 | 14 | -28 |
Net Income Before Taxes | 1552 | 5194 | 2740 | 1741 | 1587 |
Net Income After Taxes | 1513 | 4421 | 2294 | 1466 | 1330 |
Minority Interest | -2 | -2 | -1 | 0 | -2 |
Net Income Before Extra. Items | 1511 | 4419 | 2293 | 1466 | 1328 |
Net Income | 1761 | 4609 | 2293 | 1466 | 1573 |
Income Available to Common Excl. Extra. Items | 1511 | 4419 | 2293 | 1466 | 1328 |
Income Available to Common Incl. Extra. Items | 1761 | 4609 | 2293 | 1466 | 1573 |
Diluted Net Income | 1761 | 4609 | 2293 | 1466 | 1573 |
Diluted Weighted Average Shares | 2075 | 2086.5 | 2120 | 2158 | 2180 |
Diluted EPS Excluding Extraordinary Items | 0.72819 | 2.1179 | 1.0816 | 0.67933 | 0.60917 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 3.46171 | 0 |
Diluted Normalized EPS | 1.55084 | 2.38225 | 1.20956 | 1.14055 | 0.72527 |
Total Extraordinary Items | 250 | 190 | 245 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 36910 | 45718 | 29673 | 29504 | 35563 |
Cash and Short Term Investments | 18726 | 28113 | 11293 | 11234 | 15718 |
Cash | 2877 | 3396 | 3750 | 3247 | 3121 |
Cash & Equivalents | 4640 | 9011 | 5908 | 7865 | 10150 |
Short Term Investments | 11209 | 15706 | 1635 | 122 | 2447 |
Total Receivables, Net | 9894 | 9621 | 10036 | 10337 | 11036 |
Accounts Receivable - Trade, Net | 8066 | 8005 | 8217 | 8301 | 8739 |
Total Inventory | 7175 | 6666 | 7131 | 5982 | 6956 |
Prepaid Expenses | 911 | 1102 | 943 | 898 | 812 |
Other Current Assets, Total | 204 | 216 | 270 | 1053 | 1041 |
Total Assets | 117453 | 131795 | 127778 | 118370 | 145563 |
Property/Plant/Equipment, Total - Net | 12195 | 13106 | 13939 | 13746 | 15696 |
Property/Plant/Equipment, Total - Gross | 26304 | 28708 | 29894 | 28676 | 34028 |
Accumulated Depreciation, Total | -14109 | -15602 | -15955 | -14930 | -18332 |
Goodwill, Net | 29301 | 29595 | 29999 | 26524 | 35294 |
Intangibles, Net | 31644 | 34182 | 36809 | 28787 | 38719 |
Long Term Investments | 1606 | 2268 | 11611 | 10538 | 9789 |
Note Receivable - Long Term | 948 | 973 | 922 | 624 | 908 |
Other Long Term Assets, Total | 4849 | 5953 | 4825 | 8647 | 9594 |
Total Current Liabilities | 28656 | 30208 | 33059 | 28264 | 29607 |
Accounts Payable | 5146 | 5553 | 5403 | 5424 | 5556 |
Accrued Expenses | 5334 | 5100 | 5336 | 5058 | 5105 |
Notes Payable/Short Term Debt | 3635 | 3606 | 7319 | 4844 | 6430 |
Current Port. of LT Debt/Capital Leases | 2492 | 2896 | 2558 | 2248 | 3190 |
Other Current Liabilities, Total | 12049 | 13053 | 12443 | 10690 | 9326 |
Total Liabilities | 58111 | 64140 | 71180 | 62896 | 66949 |
Total Long Term Debt | 21782 | 24523 | 27978 | 22056 | 22470 |
Long Term Debt | 20244 | 22902 | 26259 | 20353 | 22470 |
Deferred Income Tax | 2686 | 3070 | 3141 | 5867 | 7475 |
Minority Interest | 81 | 167 | 68 | 77 | 78 |
Other Liabilities, Total | 4906 | 6172 | 6934 | 6632 | 7319 |
Total Equity | 59342 | 67655 | 56598 | 55474 | 78614 |
Common Stock | 890 | 901 | 913 | 936 | 944 |
Retained Earnings (Accumulated Deficit) | 63540 | 70989 | 57157 | 59274 | 82191 |
Treasury Stock - Common | -92 | -48 | -53 | -80 | -69 |
Unrealized Gain (Loss) | -198 | 206 | |||
Other Equity, Total | -4798 | -4187 | -1419 | -4656 | -4658 |
Total Liabilities & Shareholders’ Equity | 117453 | 131795 | 127778 | 118370 | 145563 |
Total Common Shares Outstanding | 2119.61 | 2234.94 | 2256.82 | 2265.01 | 2311.17 |
Capital Lease Obligations | 1538 | 1621 | 1719 | 1703 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 45660 | 33493 | 32114 | 36910 | 36954 |
Cash and Short Term Investments | 12695 | 11174 | 12260 | 18930 | 19103 |
Cash & Equivalents | 12405 | 10885 | 12000 | 7517 | 8726 |
Short Term Investments | 290 | 289 | 260 | 11413 | 10377 |
Total Receivables, Net | 7099 | 9543 | 9183 | 8334 | 8680 |
Accounts Receivable - Trade, Net | 6819 | 9195 | 8916 | 8066 | 8422 |
Total Inventory | 5610 | 8228 | 7886 | 7175 | 6779 |
Other Current Assets, Total | 20256 | 4548 | 2785 | 2471 | 2392 |
Total Assets | 112697 | 110979 | 112241 | 117453 | 118464 |
Property/Plant/Equipment, Total - Net | 10344 | 12277 | 12348 | 12195 | 11731 |
Goodwill, Net | 23416 | 29522 | 29481 | 29301 | 28668 |
Intangibles, Net | 26418 | 28003 | 30451 | 31644 | 31888 |
Long Term Investments | 2122 | 2433 | 2555 | 2554 | 2491 |
Other Long Term Assets, Total | 4737 | 5251 | 5292 | 4849 | 6732 |
Total Current Liabilities | 48393 | 31909 | 30549 | 28656 | 28160 |
Accounts Payable | 3870 | 5350 | 5426 | 5146 | 4693 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 5602 | 8496 | 7166 | 6127 | 7204 |
Other Current Liabilities, Total | 38921 | 18063 | 17957 | 17383 | 16263 |
Total Liabilities | 74533 | 59132 | 60182 | 58111 | 57644 |
Total Long Term Debt | 19521 | 19804 | 21985 | 21782 | 21235 |
Long Term Debt | 18068 | 18259 | 20396 | 20244 | 19732 |
Capital Lease Obligations | 1453 | 1545 | 1589 | 1538 | 1503 |
Deferred Income Tax | 2457 | 2526 | 2727 | 2686 | 2719 |
Minority Interest | 81 | 84 | 83 | 81 | 78 |
Other Liabilities, Total | 4081 | 4809 | 4838 | 4906 | 5452 |
Total Equity | 38164 | 51847 | 52059 | 59342 | 60820 |
Common Stock | 825 | 842 | 842 | 890 | 890 |
Retained Earnings (Accumulated Deficit) | 37371 | 51057 | 51253 | 58544 | 60000 |
Treasury Stock - Common | -32 | -52 | -36 | -92 | -70 |
Total Liabilities & Shareholders’ Equity | 112697 | 110979 | 112241 | 117453 | 118464 |
Total Common Shares Outstanding | 2055.46 | 2068.26 | 2097.4 | 2119.61 | 2150.98 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 6955 | 24018 | 8071 | 7147 | 12800 |
Cash From Operating Activities | 14236 | 15071 | 13650 | 13625 | 14272 |
Cash From Operating Activities | 1873 | 1807 | 2088 | 1852 | 1783 |
Amortization | 5308 | 4306 | 4376 | 3974 | 3428 |
Non-Cash Items | 4404 | -11714 | 3842 | 3369 | -2315 |
Cash Taxes Paid | 1975 | 2342 | 1833 | 1876 | 1506 |
Cash Interest Paid | 696 | 664 | 703 | 793 | 816 |
Changes in Working Capital | -4304 | -3346 | -4727 | -2717 | -1424 |
Cash From Investing Activities | 1468 | 4208 | -13182 | -2226 | -5591 |
Capital Expenditures | -2671 | -2971 | -2585 | -2257 | -2648 |
Other Investing Cash Flow Items, Total | 4139 | 7179 | -10597 | 31 | -2943 |
Cash From Financing Activities | -20562 | -16264 | -2208 | -13627 | -4244 |
Financing Cash Flow Items | 55 | 94 | -199 | 3307 | -119 |
Total Cash Dividends Paid | -7506 | -7368 | -6987 | -6645 | -6966 |
Issuance (Retirement) of Stock, Net | -10552 | -3004 | -2094 | -5332 | -1336 |
Issuance (Retirement) of Debt, Net | -2559 | -5986 | 7072 | -4957 | 4177 |
Foreign Exchange Effects | -32 | -266 | 286 | 69 | -26 |
Net Change in Cash | -4890 | 2749 | -1454 | -2159 | 4411 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 2294 | 6955 | 5489 | 3914 | 2219 |
Cash From Operating Activities | 2957 | 14236 | 10125 | 5404 | 1649 |
Cash From Operating Activities | 377 | 7181 | 5233 | 3207 | 1405 |
Amortization | 1619 | ||||
Non-Cash Items | 1085 | 4404 | 3417 | 2164 | 918 |
Cash Taxes Paid | 348 | 1975 | 1559 | 1239 | 633 |
Cash Interest Paid | 123 | 696 | 475 | 308 | 110 |
Changes in Working Capital | -2418 | -4304 | -4014 | -3881 | -2893 |
Cash From Investing Activities | 10621 | 1468 | 2935 | -2263 | 9365 |
Capital Expenditures | -470 | -2671 | -2024 | -1442 | -859 |
Other Investing Cash Flow Items, Total | 11091 | 4139 | 4959 | -821 | 10224 |
Cash From Financing Activities | -9202 | -20562 | -16568 | -11830 | -9528 |
Financing Cash Flow Items | -169 | 55 | 99 | 97 | 22 |
Total Cash Dividends Paid | -7255 | -7506 | -7506 | -7506 | -7506 |
Issuance (Retirement) of Stock, Net | -2727 | -10552 | -7874 | -5156 | -2448 |
Issuance (Retirement) of Debt, Net | 949 | -2559 | -1287 | 735 | 404 |
Foreign Exchange Effects | 107 | -32 | -173 | -93 | -41 |
Net Change in Cash | 4483 | -4890 | -3681 | -8782 | 1445 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.3489 | 121820582 | 0 | 2022-12-31 | LOW |
Sandoz Family | Other Insider Investor | 3.9262 | 89417347 | 281387 | 2023-10-04 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.7895 | 63531133 | 1299090 | 2023-09-30 | LOW |
UBS Asset Management (Switzerland) | Investment Advisor | 2.4548 | 55906821 | 176139 | 2022-12-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.3806 | 54217976 | 0 | 2022-12-31 | LOW |
Credit Suisse Funds AG | Investment Advisor/Hedge Fund | 2.1663 | 49335879 | -677105 | 2022-12-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.9169 | 43657691 | -98523 | 2023-09-30 | LOW |
Zürcher Kantonalbank (Asset Management) | Bank and Trust | 1.1699 | 26643704 | -83783 | 2023-09-30 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.9161 | 20863639 | 608108 | 2023-09-30 | LOW |
Artisan Partners Limited Partnership | Investment Advisor | 0.7657 | 17438508 | 97459 | 2023-09-30 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 0.7442 | 16949270 | -57400 | 2023-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5744 | 13081380 | 2934 | 2023-09-30 | LOW |
Capital Research Global Investors | Investment Advisor | 0.5466 | 12449633 | -629519 | 2023-09-30 | LOW |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.5435 | 12377422 | 38670 | 2023-09-30 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.5245 | 11946070 | -138667 | 2023-06-30 | LOW |
California Public Employees' Retirement System | Pension Fund | 0.5222 | 11892523 | 2527466 | 2022-06-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.4086 | 9305832 | 96874 | 2023-08-31 | LOW |
MFS Investment Management | Investment Advisor/Hedge Fund | 0.374 | 8518108 | 259838 | 2023-09-30 | LOW |
Nuveen LLC | Pension Fund | 0.3733 | 8500770 | -43383 | 2023-09-30 | LOW |
Fidelity International | Investment Advisor | 0.272 | 6195340 | -13114 | 2023-09-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Novartis - CHF Company profile
Novartis AG (NVS) is a global pharmaceutical company. Founded in 1996 through a merger of Ciba-Geigy and Sandoz, Novartis is headquartered in Basel, Switzerland. The firm has two divisions: Innovative Medicines and Sandoz.
Innovative Medicines offer prescription medicines and create treatments in areas of respiratory, ophthalmology, neuroscience, immunology, hepatology, dermatology, cardiovascular, renal and metabolism.
Sandoz develops, manufactures and markets generic pharmaceuticals and biosimilars. Sandoz products include: Adakveo (crizanlizumab), Afinitor Disperz/Votubia (everolimus) and Arzerra (ofatumumab) for Oncology; and Aimovig (erenumab) for neuroscience.
In 2020, in response to the pandemic, the company collaborated with Molecular Partners to develop ensovibep, a DARPin therapeutic candidate designed for potential use against Covid-19.
The company’s shares have been listed on the New York Stock Exchange (NYSE) since 2000. Novartis AG stock is traded under the ticker symbol NVS. You can track live NVS share value and price history at Capital.com.
Industry: | Pharmaceuticals (NEC) |
Lichtstrasse 35
BASEL
BASEL-STADT 4056
CH
Income Statement
- Annual
- Quarterly
News

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com